Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

New Treatments for Cancer

New Treatments for Cancer

In this article, after briefly discussing the development and approval processes for new drugs, we will describe new cancer drugs approved for use by the American Food and Drug Administration (FDA) in 2014... Drugs are products used to diagnose, treat, or prevent diseases that affect the body's function or structure. Any new drug to be introduced must undergo a rigorous evaluation and approval process. Although every country has its own approval, licensing, and reimbursement mechanisms for new drugs, the leading institution in this field is the American Food and Drug Administration.

Drug Approval Processes:

Early Testing: These are laboratory studies conducted after the discovery of a potential drug to test how it interacts with living cells and how toxic it is.

Animal Testing: A drug that shows promise after laboratory studies may be used in animal experiments to test its safety. This also provides information about its side effects and therapeutic potential.

Investigational New Drug Applications:

If laboratory and animal studies produce promising results, the manufacturer applies to the FDA to conduct investigational new drug studies (clinical trials).

Clinical Trials: If the FDA approves investigational new drug studies, clinical trials involving human participants begin. Clinical trials are divided into phases:

  • Phase 1 trials, typically involve fewer than 100 participants, and their main purpose is to test drug safety. Participants are usually healthy volunteers.
  • Phase 2 trials, are clinical trials involving hundreds of participants. The most appropriate drug dose for specific diseases and conditions is investigated. Participants are usually patients.
  • Phase 3 trials, are studies involving hundreds or thousands of participants. The drug's safety and effectiveness are tested. In these studies, the investigational drug is usually compared with products that have no drug activity, called placebos, or with other drugs previously approved in the investigational drug's field.

Approved New Drug Applications:

After clinical trials are completed, the manufacturer submits a new drug application. The FDA closely reviews standard new drugs for 10 months and highly important new drugs for 6 months. If the FDA ultimately approves the drug, its prescribing information is prepared and it is marketed.

Postmarketing Monitoring:

After a drug is approved, its prescribing information may be updated, mostly regarding side effects. The manufacturer may apply for safety updates, and physicians or patients may report serious side effects related to the drug.

We have briefly discussed the development processes for a new drug. Now let us examine several important drugs approved by the FDA for use in cancer in 2014:

Akynzeo (Netupitant and Palonosetron)

Approved by the FDA on 10 October 2014, Akynzeo is a supportive drug developed to treat chemotherapy-induced nausea and vomiting by combining two separate drugs. Netupitant acts through Substance P, which is involved in pain, while palonosetron acts at the site where a molecule called 5HT3 (serotonin) should bind. Akynzeo offers an advantage in preventing nausea and vomiting, side effects that may begin suddenly or occur later in patients receiving chemotherapy. It produces the general side effects caused by most cancer drugs.

Beleodaq (Belinostat)

Approved by the FDA on 3 July 2014, Beleodaq is used for peripheral T-cell lymphomas (PTCL), a rare, rapidly developing form of lymphatic cancer that has recurred after treatment or has never responded to treatment. The 3rd drug approved for PTCL treatment, Beleodaq causes cancer cell death by preventing the action of HDACs (histone deacetylase), a molecule involved in the cell life cycle. Beleodaq has expanded available treatment options. It causes the general side effects associated with most cancer drugs.

Blincyto (Blinatumomab)

Approved by the FDA on 3 December 2014, Blincyto is used in patients diagnosed with treatment-resistant B-cell acute lymphoblastic leukemia. This leukemia is a blood cancer characterized by a marked increase in inactive B cells in the bone marrow. Blincyto engages lymphocytes that fight cancer cells through CD19 and CD3. It is the first drug approved with this mechanism of action. Difficulty breathing and low blood pressure are its most important side effects.

Cyramza (Ramucirumab)

Another drug approved by the FDA on 12 December 2014 is Cryamza. It has begun to be used to treat advanced (metastatic) non-small cell lung cancers. Non-small cell cancers are the most common type of lung cancer. Cryamza works by preventing the formation of new blood vessels that feed the tumor. It has been found beneficial when used with other chemotherapy drugs proven effective in lung cancer treatment (such as docetaxel). Side effects such as high blood pressure and diarrhea have been observed.

Keytruda (Pembrolizumab)

Approved by the FDA on 4 September 2014, Keytruda is used to treat melanoma that has not responded to other drugs, has progressed, or cannot be surgically removed. Melanoma is cancer of the melanocytes that give skin its color. It works by blocking the intracellular action of a molecule called PD1, which suppresses the immune system. Although Keytruda is the sixth drug approved for melanoma treatment since 2011, it is the first drug to act on the cellular pathway. It causes the general side effects associated with most immunotherapy drugs.

Lynparza (Olaparib)

Approved by the FDA on 19 December 2014, Lynparza has begun to be used to treat women with advanced ovarian cancer who have a mutation (genetic change) in the BRCA gene. Lynparza works by blocking the PARP enzyme, which repairs DNA damage. In addition to the general side effects associated with most cancer drugs, caution is needed regarding its potential to cause myelodysplastic syndrome/acute myeloid leukemia.

Opdivo (Nivolumab)

Approved by the FDA on 4 March 2014, Opdivo has begun to be used in patients with advanced squamous cell lung cancer when they develop a lack of response after platinum-containing drugs (cisplatin, carboplatin), which are called standard treatment. Opdivo blocks the activity of the PD-1 protein, which suppresses our immune cells, allowing these cells to continue functioning. Opdivo is an immunotherapy drug previously also approved for melanoma treatment. Its most important side effect has been described as heat rash.

Zydelig (Idelalisib)

Approved by the FDA on 23 July 2014, Zydelig has begun to be used for relapsed non-Hodgkin lymphoma, a type of relapsed leukemia, and, in combination, relapsed chronic lymphocytic leukemia. Its mechanism of action involves suppressing PI3K (phosphoinositide 3 kinase), a small molecule that can lead to blood cancers, through intracellular pathways.

Zykadia (Ceritinib)

Approved by the FDA on 29 April 2014, Zykadia is an ALK (anaplastic lymphoma kinase) tyrosine kinase inhibitor. The ALK tyrosine kinase receptor is an enzyme encoded by the ALK gene in humans. When it fuses (combines) with certain other genes, it can trigger various diseases. The EML4-ALK fusion gene accounts for approximately %5 of lung adenocarcinomas. Ceritinib suppresses the activity of this fused gene. This drug was approved for the following patient group: ALK (anaplastic lymphoma kinase)-positive metastatic non-small cell lung cancer previously treated with crizotinib, another ALK tyrosine kinase inhibitor. Zykadia, the 4th drug to receive FDA approval for lung cancer, produces the general side effects associated with most cancer drugs.

Somatuline (Lanreotide)

Approved by the FDA on 16 December 2014, Somatuline is used to treat gastroenteropancreatic neuroendocrine tumors that are well or moderately similar to normal body tissue, could not be surgically removed, and are locally advanced or have spread. Gastroenteropancreatic neuroendocrine tumors are a subgroup of tumors arising from the nervous and hormonal systems that affect organs such as the stomach, pancreas, and bowel. It is believed to work by performing functions similar to somatostatin, a hormone secreted in our bodies that mainly affects growth. Vomiting has been reported as its most common side effect.

Jakafi, Jakavi (Ruxolitinib)

Approved by the FDA on 4 December 2014, Jakafi is used to treat patients with polycythemia vera whose response to hydroxyurea, which reduces blood cells, is inadequate. Polycythemia vera is a stem cell disease caused by excessive production of erythrocytes (red blood cells) in the bone marrow. Jakafi drugs work by blocking the function of molecules called JAK1 and JAK2 (Janus kinase), which are involved in blood cell production and immune responses. Their most common side effects are those associated with most cancer drugs, such as anemia and headache.

Altuzan (Bevacizumab)

Approved by the FDA on 14 November 2014, Altuzan has begun to be used with drugs such as paclitaxel and topotecan to treat platinum (cisplatin, carboplatin)-resistant recurrent cancers of the ovary, fallopian tube, or peritoneum, the lining of our abdomen. The fallopian tube is the section between the uterus and ovaries. Altuzan works by preventing the formation of new blood vessels that feed the tumor. Previously proven effective in many cancers (large bowel, brain, cervix), Altuzan has thus become part of the treatment of ovarian, fallopian tube, and peritoneal cancers. Its most common side effects are high blood pressure, reduced neutrophils, a type of blood cell, and damage to the nervous system.

Purixan (Mercaptopurine)

Approved by the FDA on 28 April 2014, Purixan is used with other drugs to treat acute lymphoblastic leukemia (ALL). Mercaptopurine is a complementary component of ALL treatment. It causes cancer cell death by activating the action of an enzyme called HGPRTase. Its side effects include suppression of bone marrow, liver, and immune system function.

Sylvant (Siltuximab)

Approved by the FDA on 23 April 2014, Sylvant is used to treat multicentric Castleman disease in the absence of the human immunodeficiency virus HIV and the herpesvirus HHV -type 8-. Castleman disease is an overgrowth of lymph nodes resulting from an abnormal increase in B lymphocytes and plasma cells, blood cells produced in lymphoid tissues. Siltuximab blocks the function of a molecule called IL-6 involved in producing these cells. The most common side effects are itching, weight gain, heat rash, excessive urea production, and upper respiratory tract infections.

Imbruvica (Ibrutinib)

Approved by the FDA on 12 February 2014, Imbruvica is used in previously treated patients diagnosed with chronic lymphocytic leukemia. Ibrutinib had previously received FDA approval in 2013, in November, for use in mantle cell lymphoma, a rare lymphoma. By binding to the active part of a small molecule called BTK, ibrutinib prevents B cells, which play an effective role in immunity, from performing their functions. Nonclinical studies also indicate that it prevents cancerous B cells from multiplying. It causes the general side effects associated with most cancer drugs.

Arzerra (Ofatumumab)

Approved by the FDA on 17 April 2014, Arzerra is used with chlorambucil in patients diagnosed with chronic lymphocytic leukemia who have not previously responded to fludarabine-based drug treatment. Ofatumumab acts on a molecule called CD20 on B cells, causing these cells to break down. Its most common side effects are low white blood cell counts (neutropenia), headache, susceptibility to herpesvirus, lower respiratory tract infections, joint pain, and abdominal pain.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

New Treatments for Cancer

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy